Revisiting the Serotonin Hypothesis: Implications for Major Depressive Disorders

Molecular Neurobiology

Volumn 53, Issue 5, 2016, Pages 2778-2786

  Fakhoury, Marc ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

G protein coupling; Gene knockout; Major depressive disorder; Serotonin; Serotonin receptor; Transporter

Indexed keywords

AUTORECEPTOR; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; ANTIDEPRESSANT AGENT;

ANTIDEPRESSANT ACTIVITY; DISEASE MODEL; GENE ACTIVITY; GENE DELETION; HUMAN; INTERNALIZATION; KNOCKOUT MOUSE; MAJOR DEPRESSION; MOLECULAR INTERACTION; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION; ANIMAL; BIOLOGICAL MODEL; DRUG EFFECTS; ENDOCYTOSIS; METABOLISM;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DISEASE MODELS, ANIMAL; ENDOCYTOSIS; HUMANS; MODELS, BIOLOGICAL; SEROTONIN;

EID: 84961287820     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-015-9152-z     Document Type: Review

References (99)

1. Pae CU, Wang SM, Han C, Lee SJ, Patkar AA, Masand PS et al (2014) Vortioxetine: a meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. J Psychiatry Neurosci 39:140120
2. Fakhoury M (2015) New insights into the neurobiological mechanisms of major depressive disorders. GenHosp Psychiatry 37:172–177
3. Kenneson A, Funderburk JS, Maisto SA (2013) Substance use disorders increase the odds of subsequent mood disorders. Drug Alcohol Depend 133:338–343
4. AmericanPsychiatric Association (2003) Diagnostic and statistical manual of mental disorders, 5th edn. American Psychiatric Press, Washington, DC
5. Saveanu RV, Nemeroff CB (2012) Etiology of depression: genetic and environmental factors. Psychiatr Clin N Am 35:51–71
6. Domínguez-López S, Howell R, Gobbi G (2012) Characterization of serotonin neurotransmission in knockout mice: implications for major depression. Rev Neurosci 23:429–443
7. Meyer JH (2007) Imaging the serotonin transporter during major depressive disorder and antidepressant treatment. J Psychiatry Neurosci 32:86–102
8. Hoffman BJ, Mezey E, Brownstein MJ (1991) Cloning of a serotonin transporter affected by antidepressants. Science 254:579–580
9. Carr GV, Lucki I (2011) The role of serotonin receptor subtypes in treating depression: a review of animal studies. Psychopharmacology (Berl) 213:265–287
10. Savitz J, Lucki I, Drevets WC (2009) 5-HT(1A) receptor function in major depressive disorder. Prog Neurobiol 88:17–31
11. Stamford JA, Davidson C, McLaughlin DP, Hopwood SE (2000) Control of dorsal raphé 5-HT function by multiple 5-HT(1) autoreceptors: parallel purposes or pointless plurality? Trends Neurosci 23:459–465
12. Kasamo K, Suzuki T, Tada K, Ueda N, Matsuda E, Ishikawa K et al (2001) Endogenous 5-HT tonically inhibits spontaneous firing activity of dorsal hippocampus CA1 pyramidal neurons through stimulation of 5-HT(1A) receptors in quiet awake rats: in vivo electrophysiological evidence. Neuropsychopharmacology 24:141–151
13. Anthony JP, Sexton TJ, Neumaier JF (2000) Antidepressant-induced regulation of 5-HT(1b) mRNA in rat dorsal raphe nucleus reverses rapidly after drug discontinuation. J Neurosci Res 61:82–87
14. Celada P, Puig M, Amargós-Bosch M, Adell A, Artigas F (2004) The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 29:252–265
15. Albert PR, Benkelfat C (2013) The neurobiology of depression—revisiting the serotonin hypothesis. II. Genetic, epigenetic and clinical studies. Philos Trans R Soc Lond B Biol Sci 368:20120535
16. Maurer-Spurej E, Pittendreigh C, Misri S (2007) Platelet serotonin levels support depression scores for women with postpartum depression. J Psychiatry Neurosci 32:23–29
17. Ogawa S, Fujii T, Koga N, Hori H, Teraishi T, Hattori K et al (2014) Plasma L-tryptophan concentration in major depressive disorder: new data and meta-analysis. J Clin Psychiatry 75:e906–e915
18. Booij L, Van der Does W, Benkelfat C, Bremner JD, Cowen PJ, Fava M et al (2002) Predictors of mood response to acute tryptophan depletion. A reanalysis. Neuropsychopharmacology 27:852–861
19. El Mansari M, Guiard BP, Chernoloz O, Ghanbari R, Katz N et al (2010) Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder. CNS Neurosci Ther 16:e1–e17
20. Vaswani M, Linda FK, Ramesh S (2003) Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 27:85–102
21. Marazziti D, Golia F, Consoli G, Presta S, Pfanner C, Carlini M et al (2008) Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients. CNS Spectr 13:971–976
22. Emslie GJ, Heiligenstein JH, Wagner KD, Hoog SL, Ernest DE, Brown E et al (2002) Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. J Am Acad Child Adolesc Psychiatry 41:1205–1215
23. Muijsers RB, Plosker GL, Noble S (2002) Spotlight on sertraline in the management of major depressive disorder in elderly patients. CNS Drugs 16:789–794
24. Montañez S, Daws LC, Gould GG, Frazer A (2003) Serotonin (5-HT) transporter (SERT) function after graded destruction of serotonergic neurons. J Neurochem 87:861–867
25. Schloss P, Williams DC (1998) The serotonin transporter: a primary target for antidepressant drugs. J Psychopharmacol 12:115–121
26. Lesch KP, Wolozin BL, Murphy DL, Riederer P (1993) Isolation of a cDNA encoding the human brain serotonin transporter. J Neurochem 60:2319–2322
27. Ramamoorthy S, Bauman AL, Moore KR, Han H, Yang-Feng T, Chang AS et al (1993) Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc Natl Acad Sci USA 90:2542–2546
28. Lebrand C, Cases O, Adelbrecht C, Doye A, Alvarez C, El Mestikawy S et al (1996) Transient uptake ans storage of serotonin in developing thalamic neurons. Neuron 17:823–835
29. Hansson SR, Mezey É, Hoffman BJ (1998) Serotonin transporter messenger RNA in the developing rat brain: early expression in serotonergic neurons and transient expression in non-serotonergic neurons. Neuroscience 83:1185–1201
30. Austin MC, Bradley CC, Mann JJ, Blakely RD (1994) Expression of serotonin transporter messenger mRNA in the human brain. J Neurochem 62:2362–2367
31. Caspi A, Sugden K, Moffitt TE, Taylor A, Craig IW, Harrington H et al (2003) Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301:386–389
32. Eley TC, Sugden K, Corsico A, Gregory AM, Sham P, McGuffin P et al (2004) Gene-environment interaction analysis of serotonin system markers with adolescent depression. Mol Psychiatry 9:908–915
33. Oya S, Choi SR, Hou C, Mu M, Kung MP, Acton PD et al (2000) 2-((2-((dimethylamino)methyl)phenyl)thio)-5-iodophenylamine (ADAM): an improved serotonin transporter ligand. Nucl Med Biol 27:249–254
34. Holley A, Simonson B, Kivell BM (2013) MDMA regulates serotonin transporter function via a Protein kinase C dependent mechanism. J Addict Prev 1:5
35. Zhou Z, Zhen J, Karpowich NK, Law CJ, Reith ME, Wang DN (2009) Antidepressant specificity of serotonin transporter suggested by three LeuT-SSRI structures. Nat Struct Mol Biol 16:652–657
36. Haase J, Killian AM, Magnani F, Williams C (2001) Regulation of the serotonin transporter by interacting proteins. Biochem Soc Trans 29:722–728
37. Lau T, Horschitz S, Berger S, Bartsch D, Schloss P (2008) Antidepressant-induced internalization of the serotonin transporter in serotonergic neurons. FASEB J 22:1702–1714
38. Raymond JR, Mukhin YV, Gettys TW, Garnovskaya MN (1999) The recombinant 5-HT1A receptor: G protein coupling and signalling pathways. Br J Pharmacol 127:1751–1764
39. Riad M, Garcia S, Watkins KC, Jodoin N, Doucet E, Langlois X et al (2000) Somatodendritic localization of 5-HT1A and preterminal axonal localization of 5-HT1B serotonin receptors in adult rat brain. J Comp Neurol 417:181–194
40. Le Poul E, Boni C, Hanoun N, Laporte AM, Laaris N, Chauveau J et al (2000) Differential adaptation of brain 5-HT1A and 5-HT1B receptors and 5-HT transporter in rats treated chronically with fluoxetine. Neuropharmacology 39:110–122
41. Riad M, Watkins KC, Doucet E, Hamon M, Descarries L (2001) Agonist-induced internalization of serotonin-1A receptors in the dorsal raphe nucleus (autoreceptors) but not hippocampus (heteroreceptors). J Neurosci 21:8378–8386
42. Hesselgrave N, Parsey RV (2013) Imaging the serotonin 1A receptor using [11C]WAY100635 in healthy controls and major depression. Philos Trans R Soc Lond B Biol Sci 368:20120004
43. Toth M (2003) 5-HT1A receptor knockout mouse as a genetic model of anxiety. Eur J Pharmacol 463:177–184
44. Dekeyne A, Rivet JM, Gobert A, Millan MJ (2001) Generalization of serotonin (5-HT)1A agonists and the antipsychotics, clozapine, ziprasidone and S16924, but not haloperidol, to the discriminative stimuli elicited by PD128,907 and 7-OH-DPAT. Neuropharmacology 40:899–910
45. Riad M, Zimmer L, Rbah L, Watkins KC, Hamon M, Descarries L (2004) Acute treatment with the antidepressant fluoxetine internalizes 5-HT1A autoreceptors and reduces the in vivo binding of the PET radioligand [18F]MPPF in the nucleus raphe dorsalis of rat. J Neurosci 24:5420–5426
46. Baune BT, Hohoff C, Roehrs T, Deckert J, Arolt V, Domschke K (2008) Serotonin receptor 1A–1019C/G variant: impact on antidepressant pharmacoresponse in melancholic depression? Neurosci Lett 436:111–115
47. Eriksson TM, Alvarsson A, Stan TL, Zhang X, Hascup KN, Hascup ER et al (2013) Bidirectional regulation of emotional memory by 5-HT1B receptors involves hippocampal p11. Mol Psychiatry 18:1096–1105
48. Ruf BM, Bhagwagar Z (2009) The 5-HT1B receptor: a novel target for the pathophysiology of depression. Curr Drug Targets 10:1118–1138
49. Hamblin MW, Metcalf MA, McGuffin RW, Karpells S (1992) Molecular cloning and functional characterization of a human 5-HT1B serotonin receptor: a homologue of the rat 5-HT1B receptor with 5-HT1D-like pharmacological specificity. Biochem Biophys Res Commun 184:752–759
50. Maroteaux L, Saudou F, Amlaiky N, Boschert U, Plassat JL, Hen R (1992) Mouse 5HT1B serotonin receptor: cloning, functional expression, and localization in motor control centers. Proc Natl Acad Sci U S A 89:3020–3304
51. Voigt MM, Laurie DJ, Seeburg PH, Bach A (1991) Molecular cloning and characterization of a rat brain cDNA encoding a 5-hydroxytryptamine1B receptor. EMBO J 10:4017–4023
52. Morikawa H, Manzoni OJ, Crabbe JC, Williams JT (2000) Regulation of central synaptic transmission by 5-HT(1B) auto- and heteroreceptors. Mol Pharmacol 58:1271–1278
53. Clark MS, Neumaier JF (2001) The 5-HT1B receptor: behavioral implications. Psychopharmacol Bull 35:170–185
54. Tatarczyńska E, Kłodzińska A, Stachowicz K, Chojnacka-Wójcik E (2004) Effects of a selective 5-HT1B receptor agonist and antagonists in animal models of anxiety and depression. Behav Pharmacol 15:523–534
55. Hannon J, Hoyer D (2008) Molecular biology of 5-HT receptors. Behav Brain Res 195:198–213
56. Yeung LY, Kung HF, Yew DT (2010) Localization of 5-HT1A and 5-HT2A positive cells in the brainstems of control age-matched and Alzheimer individuals. Age (Dordr) 32:483–495
57. Meyer JH, McMain S, Kennedy SH, Korman L, Brown GM, DaSilva JN et al (2003) Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am J Psychiatry 160:90–99
58. Shelton RC, Sanders-Bush E, Manier DH, Lewis DA (2009) Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A. Neuroscience 158:1406–1415
59. Pullar IA, Carney SL, Colvin EM, Lucaites VL, Nelson DL, Wedley S (2000) LY367265, an inhibitor of the 5-hydroxytryptamine transporter and 5-hydroxytryptamine(2A) receptor antagonist: a comparison with the antidepressant, nefazodone. Eur J Pharmacol 407:39–46
60. Kettle CJ, Cheetham SC, Martin KF, Prow MR, Heal DJ (1999) The effects of the peptide-coupling agent, EEDQ, on 5-HT2A receptor binding and function in rat frontal cortex. Neuropharmacology 38:1421–1430
61. Pehek EA, Nocjar C, Roth BL, Byrd TA, Mabrouk OS (2006) Evidence for the preferential involvement of 5-HT2A serotonin receptors in stress- and drug-induced dopamine release in the rat medial prefrontal cortex. Neuropsychopharmacology 31:265–277
62. Ohkura M, Tanaka N, Kobayashi H, Wada A, Nakai J, Yamamoto R (2005) Insulin induces internalization of the 5-HT2A receptor expressed in HEK293 cells. Eur J Pharmacol 518:18–21
63. Roth BL, Palvimaki EP, Berry S, Khan N, Sachs N, Uluer A et al (1995) 5-Hydroxytryptamine2A (5-HT2A) receptor desensitization can occur without down-regulation. J Pharmacol Exp Ther 275:1638–1646
64. Lefkowitz RJ, Shenoy SK (2005) Transduction of receptor signals by beta-arrestins. Science 308:512–517
65. Zheng H, Loh HH, Law PY (2008) Beta-arrestin-dependent mu-opioid receptor-activated extracellular signal-regulated kinases (ERKs) translocate to nucleus in contrast to G protein-dependent ERK activation. Mol Pharmacol 73:178–190
66. Foreman JC, Johansen T, Gibb AJ (2010) Textbook of receptor pharmacology, 3rd edn. CRC, Boca Raton
67. Premont RT, Gainetdinov RR (2007) Physiological roles of G protein-coupled receptor kinases and arrestins. Annu Rev Physiol 69:511–534
68. Ferguson SSG, Downey WER, Colapietro AM, Barak LS, Menard L, Caron MG (1996) Role of β-arrestins in mediating agonist-promoted G protein-coupled receptor internalization. Science 271:363–366
69. Laporte SA, Oakley RH, Zhang J, Holt JA, Ferguson SSG, Caron MG et al (1999) The beta2-adrenergic receptor/betaarrestin complex recruits the clathrin adaptor AP-2 during endocytosis. Proc Natl Acad Sci U S A 96:3712–3717
70. Grange-Midroit M, García-Sevilla JA, Ferrer-Alcón M, La Harpe R, Walzer C, Guimón J (2002) G protein-coupled receptor kinases, β-arrestin-2 and associated regulatory proteins in the human brain: postmortem changes, effect of age and subcellular distribution. Mol Brain Res 101:39–51
71. Oakley RH, Laporte SA, Holt JA, Caron MG, Barak LS (2000) Differential affinities of visual arrestin, beta arrestin1, and beta arrestin2 for G protein-coupled receptors delineate two major classes of receptors. J Biol Chem 275:17201–17210
72. Avissar S, Matuzany-Ruban A, Tzukert K, Schreiber G (2004) Beta-arrestin-1 levels: reduced in leukocytes of patients with depression and elevated by antidepressants in rat brain. Am J Psychiatry 161:2066–2072
73. Matuzany-Ruban A, Avissar S, Schreiber G (2005) Dynamics of beta-arrestin1 protein and mRNA levels elevation by antidepressants in mononuclear leukocytes of patients with depression. J Affect Disord 88:307–312
74. David DJ, Samuels BA, Rainer Q, Wang J-W, Marsteller D, Mendez I et al (2009) Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 62:479–493
75. Haenisch B, Bonisch H (2011) Depression and antidepressants: insights from knockout of dopamine, serotonin or noradrenaline re-uptake transporters. Pharmacol Ther 129:352–368
76. Song C, Leonard BE (2005) The olfactory bulbectomised rat as a model of depression. Neurosci Biobehav Rev 29:627–647
77. Romeas T, Morissette MC, Mnie-Filali O, Piñeyro G, Boye SM (2009) Simultaneous anhedonia and exaggerated locomotor activation in an animal model of depression. Psychopharmacology (Berl) 205:293–303
78. Harkin A, Kelly JP, Leonard BE (2003) A review of the relevance and validity of olfactory bulbectomy as a model of depression. Clin Neurosci Res 3:253–262
79. Watanabe A, Tohyama Y, Nguyen KQ, Hasegawa S, Debonnel G, Diksic M (2003) Regional brain serotonin synthesis is increased in the olfactory bulbectomy rat model of depression: an autoradiographic study. J Neurochem 85:469–475
80. Slotkin TA, Cousins MM, Tate CA, Seidler FJ (2005) Serotonergic cell signaling in an animal model of aging and depression: olfactory bulbectomy elicits different adaptations in brain regions of young adult vs aging rats. Neuropsychopharmacology 30:52–57
81. Yalcin I, Belzung C, Surget A (2008) Mouse strain differences in the unpredictable chronic mild stress: a four-antidepressant survey. Behav Brain Res 193:140–143
82. Krishnan V, Nestler EJ (2011) Animal models of depression: molecular perspectives. Curr Top Behav Neurosci 7:121–147
83. Liang BF, Huang F, Wang HT, Wang GH, Yuan X, Zhang MZ et al (2014) Involvement of norepinephrine and serotonin system in antidepressant-like effects of hederagenin in the rat model of unpredictable chronic mild stress-induced depression. Pharm Biol 4:1–10
84. Chourbaji S, Zacher C, Sanchis-Segura C, Dormann C, Vollmayr B, Gass P (2005) Learned helplessness: validity and reliability of depressive-like states in mice. Brain Res Brain Res Protoc 16:70–78
85. Dwivedi Y, Mondal AC, Payappagoudar GV, Rizavi HS (2005) Differential regulation of serotonin (5HT)2A receptor mRNA and protein levels after single and repeated stress in rat brain: role in learned helplessness behavior. Neuropharmacology 48:204–214
86. Jiang X, Xing G, Yang C, Verma A, Zhang L, Li H (2009) Stress impairs 5-HT2A receptor-mediated serotonergic facilitation of GABA release in juvenile rat basolateral amygdala. Neuropsychopharmacology 34:410–423
87. Venzala E, García-García AL, Elizalde N, Delagrange P, Tordera RM (2012) Chronic social defeat stress model: behavioral features, antidepressant action, and interaction with biological risk factors. Psychopharmacology (Berl) 224:313–325
88. Zhang J, Fan Y, Li Y, Zhu H, Wang L, Zhu MY (2012) Chronic social defeat up-regulates expression of the serotonin transporter in rat dorsal raphe nucleus and projection regions in a glucocorticoid-dependent manner. J Neurochem 123:1054–1068
89. Kalueff AV, Jensen CL, Murphy DL (2007) Locomotory patterns, spatiotemporal organization of exploration and spatial memory in serotonin transporter knockout mice. Brain Res 1169:87–97
90. Fabre V, Beaufour C, Evrard A, Rioux A, Hanoun N, Lesch KP et al (2000) Altered expression and functions of serotonin 5-HT1A and 5-HT1B receptors in knock-out mice lacking the 5-HT transporter. Eur J Neurosci 12:2299–2310
91. Li Q, Wichems CH, Ma L, Van de Kar LD, Garcia F, Murphy DL (2003) Brain region-specific alterations of 5-HT2A and 5-HT2C receptors in serotonin transporter knockout mice. J Neurochem 84:1256–1265
92. Gobbi G, Murphy DL, Lesch K, Blier P (2001) Modifications of the serotonergic system in mice lacking serotonin transporters: an in vivo electrophysiological study. J Pharmacol Exp Ther 296:987–995
93. Pattij T, Groenink L, Hijzen TH, Oosting RS, Maes RA, van der Gugten J et al (2002) Autonomic changes associated with enhanced anxiety in 5-HT(1A) receptor knockout mice. Neuropsychopharmacology 27:380–390
94. Janusonis S, Anderson GM, Shifrovich I, Rakic P (2006) Ontogeny of brain and blood serotonin levels in 5-HT receptor knockout mice: potential relevance to the neurobiology of autism. J Neurochem 99:1019–1031
95. Ase AR, Reader TA, Hen R, Riad M, Descarries L (2000) Altered serotonin and dopamine metabolism in the CNS of serotonin 5-HT(1A) or 5-HT(1B) receptor knockout mice. J Neurochem 75:2415–2426
96. Richardson-Jones JW, Craige CP, Nguyen TH, Kung HF, Gardier AM, Dranovsky A et al (2011) Serotonin-1A autoreceptors are necessary and sufficient for the normal formation of circuits underlying innate anxiety. J Neurosci 31:6008–6018
97. Adrien J (2004) Implication of serotonin in the control of vigilance states as revealed by knockout-mouse studies. J Soc Biol 198:30–36
98. Popa D, Léna C, Fabre V, Prenat C, Gingrich J, Escourrou P et al (2005) Contribution of 5-HT2 receptor subtypes to sleep-wakefulness and respiratory control, and functional adaptations in knock-out mice lacking 5-HT2A receptors. J Neurosci 25:11231–11238
99. Halberstadt AL, van der Heijden I, Ruderman MA, Risbrough VB, Gingrich JA, Geyer MA et al (2009) 5-HT(2A) and 5-HT(2C) receptors exert opposing effects on locomotor activity in mice. Neuropsychopharmacology 34:1958–1967